Title:
CLASS OF BIPIPERIDINE DERIVATIVES AS ANTITUMOR DRUG
Document Type and Number:
WIPO Patent Application WO/2020/108407
Kind Code:
A1
Abstract:
Provided is a compound represented by formula (I) serving as an inhibitor of cyclin-dependent kinase 7 (CDK7), a pharmaceutical composition thereof, and a method of using the same. Proposed is a use of the compound or the pharmaceutical composition. Representative compounds show anti-cell proliferation and anti-angiogenic activity. Some compounds are more effective than existing anticancer drugs on the market, such as sunitinib. Accordingly, in some aspects, the compound can be used for preparing drugs for treating abnormal cell proliferation or diseases related to angiogenesis, such as antitumor drugs, leukemia drugs and antiviral drugs.
Inventors:
GALONS HERVE (CN)
YU PENG (CN)
OUMATA NASSIMA (CN)
LU KUI (CN)
TENG YUOU (CN)
ZHANG QIAN (CN)
ZHAO LIANBO (CN)
YU PENG (CN)
OUMATA NASSIMA (CN)
LU KUI (CN)
TENG YUOU (CN)
ZHANG QIAN (CN)
ZHAO LIANBO (CN)
Application Number:
PCT/CN2019/120319
Publication Date:
June 04, 2020
Filing Date:
November 22, 2019
Export Citation:
Assignee:
TIANJIN UNIV OF SINCE AND TECHNOLOGY (CN)
International Classes:
C07D473/16; A61K31/52; A61P31/12; A61P35/00; A61P35/02
Domestic Patent References:
| WO2003022219A2 | 2003-03-20 |
Foreign References:
| CN107427521A | 2017-12-01 | |||
| CN101809020A | 2010-08-18 | |||
| CN105026396A | 2015-11-04 |
Other References:
WU, CHIENHUANG ET AL.: "Function-Oriented Development of CXCR4 Antagonists as Selective Human Immunodeficiency Virus(HIV)-1 Entry Inhibitors", J. MED. CHEM., vol. 58, 13 January 2015 (2015-01-13), XP055711305, ISSN: 0022-2623, DOI: 20200210151531A
Attorney, Agent or Firm:
SHENZHEN ELSON PATENT AGENT FIRM (GENERAL PARTNERSHIP) (CN)
Download PDF: